AC Immune S.A. (ACIU): Rasio kapitalisasi marang pendapatan
AC Immune's authority in targeted therapy is validated by partnerships with industry behemoths. The business valuation based on P/S demonstrates the dynamics of this confidence, where the value 8.70 reflects the metric's balance. High capital expenditures and patent protection create a steep barrier to entry. Meanwhile, the Morphomer platform ensures pricing power through the development of unique antibodies to combat Alzheimer's.
Rincian analitis perusahaan AC Immune Corp (ACIU)
- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas AC Immune|ACIU - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal AC Immune Inc|ACIU - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku AC Immune Corp|ACIU - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan AC Immune|Likuiditas darurat acimmune.com
- data bathi lan kelipatan valuasi:
ACIU - Penghasilan resik|Proyeksi bathi mangsa ngarep AC Immune|ACIU - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi AC Immune S.A.|ACIU - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan AC Immune Corp|ACIU - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) AC Immune|ACIU - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan acimmune.com|ACIU - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep AC Immune
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:ACIU acimmune.com
The multiple is calculated as the ratio of the current market capitalization of all shares to the total annual revenue, measuring the premium the market is willing to pay per unit of sales. Under tight monetary policy conditions, this price-to-sales ratio reflects the valuation of AC Immune (ACIU) and its potential in neurodegenerative disease therapies, where balance sheet stability is maintained through strategic payments from global partners.
Pesaing AC Immune
Multiplikator P/S biogen.com (BIIB)|Rasio rega marang pendapatan Neurocrine Biosciences, Inc. NBIX|RGC: Rasio kapitalisasi marang pendapatan|Axsome Therapeutics Inc - Multiplikator P/S|Rega marang dodolan ACADIA Corp|XENE: Multiplikator P/S|vikingtherapeutics.com (VKTX) - Multiplikator P/S|SUPN (Supernus) - Multiplikator P/S|Kapitalisasi marang pendapatan Catalyst Pharma (CPRX)|Multiplikator P/S DNLI|Koefisien rega marang pendapatan Harmony Corp|Biohaven Ltd. - Kapitalisasi marang pendapatan|Multiplikator P/S amylyx.com AMLX|TRVI - Rasio rega marang pendapatan|PRAX (Praxis Precision Medicines Inc) - Rasio kapitalisasi marang pendapatan|AVXL: Multiplikator P/S|Rega marang dodolan CeriBell EEG (CBLL)|Kapitalisasi marang pendapatan PRTA|Multiplikator P/S Alector Therapeutics|Rasio rega marang pendapatan Annexon (ANNX)|OMER (omeros.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Neurogene Corp NGNE|Voyager Corp (VYGR) - Rega marang dodolan|Neumora Therapeutics - Multiplikator P/S|SCLX - Multiplikator P/S|TVGN: Multiplikator P/S|Kapitalisasi marang pendapatan Alpha Cognition Inc.|Kapitalisasi marang pendapatan CGTX|IKT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SAVA|Koefisien rega marang pendapatan assertiotx.com|Rasio rega marang pendapatan Coya Therapeutics COYA|VTGN - Kapitalisasi marang pendapatan|OVID - Rasio rega marang pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Kapitalisasi marang pendapatan|CRVO (CervoMed Inc.) - Kapitalisasi marang pendapatan|Alterity Therapeutics Limited (ATHE) - Multiplikator P/S|Rasio rega marang pendapatan Clene Inc|Rasio kapitalisasi marang pendapatan PEPG (PepGen Corp)|Multiplikator P/S JUNS|RLMD - Rega marang dodolan|Multiplikator P/S ANVS (Annovis Bio, Inc.)|Multiplikator P/S Grace Therapeutics Inc GRCE|Firefly Neuroscience - Multiplikator P/S|Klotho Neurosciences Inc (KLTO) - Kapitalisasi marang pendapatan|NRSN: Multiplikator P/S|RVPH - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan MTVA|Multiplikator P/S neuraxis.com|Rasio rega marang pendapatan Helius Medical (HSDT)|passagebio.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|Minerva (NERV) - Rega marang dodolan|ATHA: Kapitalisasi marang pendapatan|ADXN - Multiplikator P/S|alzamend.com (ALZN) - Rasio rega marang pendapatan|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Protagenic Therapeutics Inc.|Rega marang dodolan Pasithea KTTA|Multiplikator P/S CRGT|Multiplikator P/S avenuetx.com (ATXI)|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|CARA - Kapitalisasi marang pendapatan|CHRO: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI: Multiplikator P/S|LBPH - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|Kapitalisasi marang pendapatan NKGen Biotech Inc (NKGN)|Rasio rega marang pendapatan NeuroBo (NRBO)|Kapitalisasi marang pendapatan Sage Therapeutics Inc SAGE|Synaptogenix, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S trevena.com TRVN|VIGL - Rasio rega marang pendapatan|WENA (anewmeds.com) - Rasio kapitalisasi marang pendapatan|CERE: Multiplikator P/S
